STOCK TITAN

PTCT Form 144: Insider sold 73,983 shares across Aug–Oct 2025

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice reports a proposed sale of 3,375 common shares by an affiliated person, scheduled approximately on 10/07/2025 through Fidelity Brokerage Services LLC on NASDAQ. The filing records the securities were acquired as an option granted on 01/07/2022 and that payment on the planned sale will be in cash. The form also lists five recent open-market sales by the same seller totaling 73,983 shares across dates from 08/15/2025 to 10/06/2025 with individual gross proceeds shown (largest single-day gross proceeds $1,508,093.64 on 09/12/2025).

The document includes the seller's representation about lack of undisclosed material adverse information and mentions Rule 10b5-1 plan language but provides no further corporate financial metrics or forward guidance. The filing is procedural and focused on disclosure of insider sales activity rather than company operational results.

Positive

  • Required disclosure filed, showing compliance with Rule 144 and transparency about intended insider sales
  • Acquisition source is documented (option grant dated 01/07/2022), clarifying the legal basis for the shares

Negative

  • Material insider selling: 73,983 shares sold in past two months, which could add selling pressure
  • Largest recent single-day gross proceeds reported $1,508,093.64 on 09/12/2025, indicating sizable dispositions

Insights

Significant ongoing insider sales, disclosed under Rule 144, may increase share supply near-term.

3,375 shares are scheduled for proposed sale on 10/07/2025, acquired under an option granted on 01/07/2022, and recent open-market disposals by the same seller total 73,983 shares across five trades with multi-hundred-thousand dollar proceeds each. These figures show active monetization of holdings rather than a single isolated disposition.

Market impact depends on trade execution size versus average daily volume and whether the sales follow a 10b5-1 plan; the filing references plan adoption language but gives no adoption date. Watch short-term volume and exchange reports over the next few trading days for price impact and whether additional Form 144s or 4s are filed.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the PTCT Form 144 filed on 10/07/2025 disclose?

It discloses a proposed sale of 3,375 common shares planned for 10/07/2025 through Fidelity Brokerage Services LLC on NASDAQ.

How were the 3,375 shares acquired according to the Form 144 for PTCT?

The shares were acquired via an option grant with the option granted on 01/07/2022 and payment for the proposed sale listed as cash.

How many shares did the insider sell in the past three months per the filing?

The filing lists five prior sales totaling 73,983 shares between 08/15/2025 and 10/06/2025.

What were the reported gross proceeds from recent insider sales?

Individual gross proceeds shown include amounts up to $1,508,093.64 on 09/12/2025; other single-day proceeds range from about $136,646.45 to $1,491,105.66.

Does the Form 144 state whether a 10b5-1 trading plan was used?

The filing contains standard 10b5-1 plan language but does not specify a plan adoption date or provide plan details.
Ptc Therapeutics

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Latest SEC Filings

PTCT Stock Data

6.10B
78.25M
2.47%
101.79%
8.36%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARREN